Skip to content

Change in AP at other companies

Eli Lilly logo
Eli LillyLLY
$2.55B+290%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$107.7M+150%
AbbVie logo
AbbVieABBV
-$1.59B-129%
Summit Therapeutics logo
Summit TherapeuticsSMMT
$6.8M+1,811%
Immunovant, Inc. logo
Immunovant, Inc.IMVT
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX

Other financials

Income statement

See full
Operating income-$82.8M-31.2%
Net income-$74.1M-33.9%
EPS (diluted)-$1.06-11.6%

Balance sheet

See full
Cash & equivalents$451.8M+323%
Total debt$8.0M-31.9%
Total assets$1.3B+81.1%

Cash flow

See full
Operating cash flow-$55.6M-14.6%
CapEx$62.0K
Free cash flow-$62.8M+7.3%

Valuation

See full
Market cap$6.81B+189%
Enterprise value$6.37B+181%

Returns & leverage

See full
Current ratio32.6×+16.8×

Where this comes from

Reported directly by Apogee Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsPayable.

The official record: Apogee Therapeutics, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Apogee Therapeutics, Inc.'s change in ap.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Apogee Therapeutics, Inc.'s change in AP?
Apogee Therapeutics, Inc. (APGE) reported change in AP of $16K in Q1 2026.
How has Apogee Therapeutics, Inc.'s change in AP changed year-over-year?
Apogee Therapeutics, Inc.'s change in AP decreased by 98.8% year-over-year, from $1.37M to $16K.
What does change in AP mean?
Increase or decrease in amounts owed to suppliers — a key working capital component affecting operating cash flow.